These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33239807)

  • 1. Burning questions about smouldering myeloma.
    DeWeerdt S
    Nature; 2020 Nov; 587(7835):S58-S59. PubMed ID: 33239807
    [No Abstract]   [Full Text] [Related]  

  • 2. The screening imperative for multiple myeloma.
    Rajkumar SV
    Nature; 2020 Nov; 587(7835):S63. PubMed ID: 33235369
    [No Abstract]   [Full Text] [Related]  

  • 3. The difficult business of assessing new therapies for smouldering multiple myeloma.
    Zonder JA
    Br J Haematol; 2018 Aug; 182(4):463-464. PubMed ID: 29767407
    [No Abstract]   [Full Text] [Related]  

  • 4. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
    Kunacheewa C; Manasanch EE
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101152. PubMed ID: 32139017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Stratification of Precursors to Multiple Myeloma in 2020.
    Chudasama R; Barth P
    R I Med J (2013); 2020 Apr; 103(3):46-47. PubMed ID: 32236162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma.
    Schmidt T; Callander N
    J Natl Compr Canc Netw; 2020 Dec; 18(12):1720-1729. PubMed ID: 33347744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
    González-Calle V; Mateos MV
    Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.
    Correa JG; Cibeira MT; Tovar N; Isola I; Pedrosa F; Díaz T; Lozano E; Magnano L; Rosiñol L; Bladé J; Fernández de Larrea C
    Br J Haematol; 2017 Dec; 179(5):849-851. PubMed ID: 27605200
    [No Abstract]   [Full Text] [Related]  

  • 9. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Willrich MAV; Murray DL; Kyle RA
    Clin Biochem; 2018 Jan; 51():38-47. PubMed ID: 28479151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physicians, paraproteins and progress: diagnosis and management of myeloma.
    Pawlyn C; Jackson GH
    Br J Hosp Med (Lond); 2019 Feb; 80(2):91-98. PubMed ID: 30746991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
    Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group.
    Bustoros M; Kastritis E; Sklavenitis-Pistofidis R; Liu CJ; Hornburg K; Kanellias N; Kim G; Liu D; Gavriatopoulou M; Marinac CR; Roussou M; Migkou M; Noonan K; Reyes K; Rivotto B; Neuse CJ; Ziogas DC; Laubach J; Terpos E; Anderson KC; Richardson PG; Ghobrial IM; Dimopoulos MA
    Am J Hematol; 2019 May; 94(5):E146-E149. PubMed ID: 30773670
    [No Abstract]   [Full Text] [Related]  

  • 13. Progress in the Management of Smoldering Multiple Myeloma.
    Schmidt TM; Callander NS
    Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models.
    Hill E; Dew A; Morrison C; Yuan C; Stetler-Stevenson M; Landgren O; Kazandjian D
    JAMA Oncol; 2021 Jan; 7(1):132-134. PubMed ID: 33211080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smoldering Myeloma Presenting with Renal Histopathology of Monoclonal Gammopathy of Renal Significance: Adding to the Complexity.
    Kousios A; Duncan N; Charif R; Roufosse C
    J Am Soc Nephrol; 2018 Dec; 29(12):2901. PubMed ID: 30377233
    [No Abstract]   [Full Text] [Related]  

  • 16. Smoldering multiple myeloma 40 years later: a story of unintended disease.
    Yavorkovsky LL
    Expert Rev Hematol; 2021 Feb; 14(2):149-153. PubMed ID: 33430658
    [No Abstract]   [Full Text] [Related]  

  • 17. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management.
    Maciocia N; Wechalekar A; Yong K
    Hematol Oncol; 2017 Dec; 35(4):432-439. PubMed ID: 27804161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smoldering multiple myeloma: Reviewing the rationale for intervention.
    Gertz M
    Leuk Lymphoma; 2022 Sep; 63(9):2033-2040. PubMed ID: 35532298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CME: Multiple Myeloma - a Review].
    Bräutigam M; Biskup E
    Praxis (Bern 1994); 2018 Jul; 107(14):749-754. PubMed ID: 29969971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.